![]() |
市场调查报告书
商品编码
1951151
高解析度熔融分析市场-全球产业规模、份额、趋势、机会与预测:产品与服务、应用、终端用户、地区与竞争格局,2021-2031年High-Resolution Melting Analysis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product and Service, By Application, By End User, By Region & Competition, 2021-2031F |
||||||
全球高解析度熔融分析市场预计将从 2025 年的 25.9 亿美元成长到 2031 年的 45.4 亿美元,复合年增长率为 9.81%。
高解析度熔解曲线分析是一种专门用于检测核酸序列中基因突变的技术,其原理是透过观察双链DNA结合染料在热变性过程中的萤光变化。与定序相比,此方法速度更快、成本更低,因此市场成长主要得益于其速度优势,使其成为大规模基因分型和甲基化研究的理想选择。此外,感染疾病和遗传性疾病的日益增加也推动了这类便利诊断工具的需求。根据欧洲医疗技术协会(MedTech Europe)2024年发布的报告,欧洲医疗技术产业的价值约为1,700亿欧元,其中体外诊断是主要驱动力,凸显了支撑这些分析方法的强大产业生态系统。
| 市场概览 | |
|---|---|
| 预测期 | 2027-2031 |
| 市场规模:2025年 | 25.9亿美元 |
| 市场规模:2031年 | 45.4亿美元 |
| 复合年增长率:2026-2031年 | 9.81% |
| 成长最快的细分市场 | 试剂和耗材 |
| 最大的市场 | 北美洲 |
然而,由于成本下降和次世代定序技术的广泛应用,市场面临巨大的障碍。这些竞争技术在识别罕见变异方面具有更高的灵敏度和多重分析能力,在复杂的临床场景中,其分辨率往往优于熔解曲线分析。因此,需要进行全面基因组分析的实验室越来越多地选择定序平台而非熔解曲线分析,这一趋势可能会限制熔解曲线分析在高阶诊断领域的应用。
感染疾病和遗传疾病的日益增多是全球高解析度熔解曲线分析市场的主要驱动力,催生了对快速且经济实惠的突变扫描能力的需求。日益增长的健康负担促使临床检查室采用熔解曲线分析技术,该技术绕过了定序的复杂性,能够有效地识别病原体和单核苷酸多态性(SNP)。例如,美国癌症协会于2025年1月发布的《2025年癌症事实与数据》预测,当年美国新增癌症病例将超过200万例,凸显了普及基因组分析的迫切性。传染病的蔓延进一步加剧了这项需求。 2025年9月,美国疾病管制与预防中心(CDC)报告称,2024年记录性行为感染病例超过220万例,凸显了公共卫生领域诊断工作的巨大规模。
此外,热感循环和qPCR仪器的技术进步透过优化工作流程效率和灵敏度,在市场成长中发挥关键作用。现代系统具有更高的温度均匀性和更先进的演算法,简化了高通量筛检和复杂的熔解曲线分析。这些创新降低了准入门槛,使更多研究和诊断实验室能够采用这项技术进行基因分型和甲基化研究。该行业的强劲势头也体现在财务业绩中。例如,赛默飞世尔科技公司在2025年1月公布,第四季营收成长5%至114亿美元,并将这项业绩归功于公司先进诊断和分析仪器的持续普及。
全球高解析度熔解曲线分析市场面临的主要障碍是次世代定序(NGS) 成本的下降和日益普及。这种竞争方法具有更优异的多重检测能力和灵敏度,能够同时检测罕见突变和多种基因变异,其性能标准往往是熔解曲线分析无法企及的。随着临床需求向全面的基因组分析发展,实验室越来越倾向于选择能够更深入揭示复杂基因结构的定序平台,从而减少对熔解曲线分析在复杂诊断应用中的依赖。
这种转变在肿瘤学和遗传疾病管理领域尤其明显,因为在这些领域,准确的突变分类至关重要。例如,美国癌症协会估计,到2024年,美国新增癌症病例数将首次超过200万例。这些复杂疾病的增加推动了对定序所提供的全面基因组数据的需求,这也直接限制了熔解曲线分析技术在高阶临床诊断中的广泛应用。
随着 CRISPR/Cas9 技术的广泛应用,高解析度熔解曲线分析 (HMA) 作为一种快速、经济高效的筛检方法,在进行高成本的定序之前,可用于检测植物和细胞株中的突变并确认基因编辑,其应用日益普及。随着研究活动的活性化,实验室越来越依赖这项技术来有效检验引导 RNA 并确认基因突变。这种研发活动的活性化意义重大。 2025 年 2 月,CRISPR Therapeutics 在其「2024 财年第四季及全年」财务报告中揭露,公司拥有约 19 亿美元的强劲现金储备。这笔资金将用于支持公司广泛的基因编辑治疗产品线,并加速突变筛检设备和试剂的使用。
同时,食品安全和农业领域正经历显着的市场成长,高解析度质谱(HRM)已成为种子品质检测、植物鑑定和高通量作物基因型鉴定的关键技术。由于此方法无需复杂的PCR后处理即可快速区分近缘植物品种,并能辨识供应链中的诈欺行为,因此正日益取代传统方法。主要服务供应商的财务表现也印证了这种检测需求的规模。 Eurofins Scientific在2025年1月公布的「2024财年」业绩中,总收入创下69.5亿欧元的纪录,这主要得益于其北美食品和饲料检测部门的持续有机增长。
The Global High-Resolution Melting Analysis Market is projected to expand from USD 2.59 Billion in 2025 to USD 4.54 Billion by 2031, reflecting a CAGR of 9.81%. High-Resolution Melting Analysis functions as a specialized technique for detecting genetic variations in nucleic acid sequences by observing fluorescence shifts in double-stranded DNA binding dyes during thermal denaturation. Market growth is primarily driven by the method's speed and cost-effectiveness compared to sequencing, rendering it ideal for extensive genotyping and methylation research. Additionally, the increasing burden of infectious diseases and genetic conditions fuels the need for such accessible diagnostic tools. As reported by MedTech Europe in 2024, the European medical technology sector was valued at approximately 170 billion Euros, with in vitro diagnostics leading the market, highlighting the strong industrial ecosystem supporting these analytical methods.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 2.59 Billion |
| Market Size 2031 | USD 4.54 Billion |
| CAGR 2026-2031 | 9.81% |
| Fastest Growing Segment | Reagents and Consumables |
| Largest Market | North America |
Conversely, the market encounters substantial hurdles due to the decreasing costs and broader availability of Next Generation Sequencing. This rival technology provides enhanced sensitivity and multiplexing abilities for identifying rare variants, often surpassing the resolution capabilities of melting analysis in intricate clinical scenarios. Consequently, laboratories that require exhaustive genomic profiling may prefer sequencing platforms over melting analysis, a trend that could constrain the latter's growth within advanced diagnostic environments.
Market Driver
The increasing prevalence of infectious diseases and genetic disorders acts as a major driver for the Global High-Resolution Melting Analysis Market, creating a demand for fast and affordable mutation scanning capabilities. As these health burdens increase, clinical laboratories are turning to melting analysis for the efficient identification of pathogens and single nucleotide polymorphisms, avoiding the complexity associated with sequencing. For example, the American Cancer Society's 'Cancer Facts & Figures 2025' from January 2025 projected over 2 million new cancer diagnoses in the United States for the year, emphasizing the urgent need for accessible genomic profiling. This demand is further intensified by the spread of communicable diseases; the Centers for Disease Control and Prevention reported in September 2025 that there were over 2.2 million recorded sexually transmitted infections in 2024, underscoring the vast diagnostic scale required in public health.
Furthermore, technological improvements in thermal cycling and qPCR instrumentation play a crucial role in market growth by optimizing workflow efficiency and sensitivity. Modern systems feature enhanced temperature uniformity and advanced algorithms that simplify high-throughput screening and the analysis of complex melt curves. These innovations lower entry barriers, enabling a wider array of research and diagnostic facilities to implement the technology for genotyping and methylation studies. The strength of this industry is reflected in financial results; for instance, Thermo Fisher Scientific reported in January 2025 that their fourth-quarter revenue rose by 5% to $11.40 billion, a performance attributed in part to the continued adoption of their sophisticated diagnostic and analytical instruments.
Market Challenge
A major obstacle for the Global High-Resolution Melting Analysis Market is the falling cost and growing accessibility of Next Generation Sequencing. This competing approach offers superior multiplexing and sensitivity, allowing for the concurrent detection of rare mutations and multiple genetic variants, achieving performance standards that melting analysis frequently fails to match. As clinical needs evolve toward comprehensive genomic profiling, laboratories often favor sequencing platforms that offer profound insights into complex genetic structures, thereby diminishing their dependence on melting analysis for high-complexity diagnostic applications.
This shift is especially evident in oncology and genetic disorder management, where precise variant classification is critical. For example, the American Cancer Society estimated that the number of new cancer cases in the United States in 2024 would exceed 2 million for the first time. The rising burden of such complex pathologies fuels the necessity for the exhaustive genomic data provided by sequencing, which directly restricts the broader adoption of melting analysis technologies within advanced clinical diagnostic settings.
Market Trends
The widespread adoption of CRISPR/Cas9 technology has established a trend wherein High-Resolution Melting is increasingly employed as a rapid, cost-efficient screening method to detect mutations and verify gene edits in plants and cell lines prior to utilizing costly sequencing. As research efforts intensify, laboratories depend on this technique to streamline the validation of guide RNA efficacy and confirm genetic alterations. This heightened development activity is significant; in February 2025, CRISPR Therapeutics reported a strong cash position of roughly $1.9 billion in their 'Fourth Quarter and Full Year 2024 Financial Results', capital which supports their extensive gene-edited therapy pipeline and drives the usage of mutation screening instruments and reagents.
Concurrently, the market is seeing substantial growth within the food safety and agricultural sectors, where HRM is essential for seed quality testing, botanical authentication, and high-throughput crop genotyping. This approach is superseding traditional methods because of its capacity to quickly differentiate closely related plant cultivars and identify supply chain adulteration without the need for intricate post-PCR processing. The magnitude of this testing demand is illustrated by the financial results of major service providers; Eurofins Scientific reported record total revenues of €6.95 billion in their January 2025 '2024 Full Year Results', a success largely driven by the continued organic expansion of their Food and Feed Testing division in North America.
Report Scope
In this report, the Global High-Resolution Melting Analysis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global High-Resolution Melting Analysis Market.
Global High-Resolution Melting Analysis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: